Citations

Clear

4847 citation(s) found for "Yu, Eric".

Real-world treatment patterns, costs, and outcomes in patients with AL amyloidosis: analysis of the Optum EHR and commercial claims databases
Zonder, Jeffrey A. , Hoffman, James E. , Wong, Sandra W., Liedtke, Michaela , Abonour, Rafat , D’Souza, Anita , Lee, Charlene, Côté, Sarah, Ammann, Eric M. , Tran, NamPhuong, Lam, Annette , Nair, Sandhya, Dispenzieri, Angela , Ammann, Eric , Lam, Annette , D'Souza, Anita , Dispenzieri, Angela , Potluri, Ravi C.

Mayo Clinic

Amyloid | October 25, 2022 | Volume: 30 | Issue: 2 | Pages: 161-168

10.1080/13506129.2022.2137400 | PMID 36282014 Get It

Positron Emission Tomography–Adapted Therapy in Bulky Stage I/II Classic Hodgkin Lymphoma: CALGB 50801 (Alliance)
LaCasce, Ann S. , Dockter, Travis , Ruppert, Amy S. , Kostakoglu, Lale , Schöder, Heiko , Hsi, Eric D. , Bogart, Jeffrey A. , Cheson, Bruce D. , Wagner‐Johnston, Nina D. , Abramson, Jeremy S. , Blum, Kristie A. , Leonard, John P. , Bartlett, Nancy L. , Hsi, Eric D , Bogart, Jeffrey , Cheson, Bruce D , Abramson, Jeremy S , Blum, Kristie A , Bartlett, Nancy L , Kostakoglu, Lale , Schöder, Heiko

Mayo Clinic

Journal of Clinical Oncology | October 21, 2022 | Volume: 41 | Issue: 5 | Pages: 1023-1034

10.1200/jco.22.00947 | PMID 36269899 Get It

PURPOSE Patients with bulky stage I/II classic Hodgkin lymphoma (cHL) are typically treated with chemotherapy followed by radiation. Late effects associated with radiotherapy include increased risk of second cancer and cardiovascular disease. We tested a positron emission tomography (PET)–adapted approach in patients with bulky, early-stage cHL, omitting radiotherapy in patients with interim PET-negative (PET−) disease and intensifying treatment in patients with PET-positive (PET+) disease. METHODS Eligible patients with bulky disease (mass > 10 cm or 1/3 the maximum intrathoracic diameter on chest x-ray) received two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by interim fluorodeoxyglucose PET (PET2). Patients with PET2–, defined as 1-3 on the 5-point scale, received four additional cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine. Patients with PET2+ received four cycles of escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone followed by 30.6 Gy involved-field radiation. RESULTS Of 94 evaluable patients, 53% were female with median age 30 years (range, 18-58 years). Eight-five (90%) had stage II disease, including 48 (51%) with stage IIB/IIBE. Seventy-eight (78%) were PET2– and 21 (22%) were PET2+. The predominant toxicity was neutropenia, with 9% of patients developing febrile neutropenia and one developing sepsis. The primary end point of 3-year progression-free survival (PFS) was 93.1% in PET2– and 89.7% in PET2+ patients. Three-year overall survival was 98.6% and 94.4%, respectively. The estimated hazard ratio comparing PFS of patients with PET2+ and patients with PET2− was 1.03 (85% upper bound 2.38) and was significantly less than the null hypothesis of 4.1 (one-sided P = .04). CONCLUSION Our study of PET-adapted therapy in bulky stage I/II cHL met its primary goal and was associated with an excellent 3-year PFS rate of 92.3% in all patients, with the majority being spared radiotherapy and exposure to intensified chemotherapy.
An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS
Stahl, Maximilian , Wei, Andrew H. , Savona, Michael R. , Xu, Mina L. , Xie, Zhuoer , Sanz, Guillermo , Sallman, David A. , Patnaik, Mrinal M. , Padron, Eric , Odenike, Olatoyosi , Nazha, Aziz , Nimer, Stephen D. , Majeti, Ravindra , Little, Richard F. , Gore, Steven D. , Kutchroo, Vijay, Kim, Tae Kon , Kim, Nina , Hasserjian, Robert P. , Greenberg, Peter L. , Fenaux, Pierre , Churpek, Jane E. , Brunner, Andrew M. , Borate, Uma , Bennett, John M. , Platzbecker, Uwe , Buckstein, Rena , Zeidan, Amer M. , Wei, Andrew H , Savona, Michael R , Xie, Zhuoer , Taylor, Justin , Sanz, Guillermo F , Santini, Valeria , Roboz, Gail J , Patnaik, Mrinal , Little, Richard F , Komrokji, Rami S , Kim, Tae Kon , Kim, Nina , Hourigan, Christopher S , Halene, Stephanie , Griffiths, Elizabeth A. , Greenberg, Peter L , Daver, Naval , Carraway, Hetty E. , Bejar, Rafael , Boultwood, Jacqueline , Loghavi, Sanam , Platzbecker, Uwe , Steensma, David P , Majeti, Ravindra , Zeidan, Amer M , Churpek, Jane E , Abdel‐Wahab, Omar , Starczynowski, Daniel T. , Santini, Valeria , Roboz, Gail J. , List, Alan F. , Komrokji, Rami S. , Hourigan, Christopher S. , Figueroa, María E. , Efficace, Fabio , Dezern, Amy Elizabeth , Della Porta, Matteo Giovanni , Daver, Naval , Boultwood, Jacqueline , Loghavi, Sanam , Bewersdorf, Jan Philipp , Steensma, David P. , Sekeres, Mikkael A. , Churpek, Jane

Mayo Clinic

Blood Advances | October 19, 2022 | Volume: 7 | Issue: 12 | Pages: 2709-2714

10.1182/bloodadvances.2022008747 | PMID 36260702 Get It

Concurrent Administration of Immune Checkpoint Inhibitors and Stereotactic Radiosurgery Is Well-Tolerated in Patients With Melanoma Brain Metastases: An International Multicenter Study of 203 Patients
Lehrer, Eric J. , Gurewitz, Jason , Bernstein, Kenneth , Fakhoury, Kareem , Rusthoven, Chad G. , Niranjan, Ajay , Wei, Zhishuo , Lunsford, L. Dade , Malouff, Timothy D. , Peterson, Jennifer , Bonney, Phillip A. , Hwang, Lindsay , Yu, Cheng , Zada, Gabriel , Deibert, Christopher P., Prasad, Rahul N. , Raval, Raju R. , Patel, Samir , Franzini, Andrea , Attuati, Luca , Mathieu, David , Trudel, Claire, Lee, Cheng-chia, Green, Sheryl , Ahluwalia, Manmeet S. , Sheehan, Jason P. , Peterson, Jennifer L., Mathieu, David , Ahluwalia, Manmeet S , Kondziolka, Douglas , Ruiz-García, Henry , Palmer, Joshua D. , Picozzi, Piero , Yang, Huai‐Che , Jones, Brianna M. , Trifiletti, Daniel M.

Mayo Clinic

Neurosurgery | October 18, 2022 | Volume: 91 | Issue: 6 | Pages: 872-882

10.1227/neu.0000000000002127 | PMID 36255215 Get It

BACKGROUND: Melanoma brain metastases are commonly treated with stereotactic radiosurgery (SRS) and immune checkpoint inhibitors (ICIs). However, the toxicity of these 2 treatments is largely unknown when administered concurrently. OBJECTIVE: To evaluate the risk of radiation necrosis (RN) with concurrent and nonconcurrent SRS and ICIs. METHODS: The guidelines from the Strengthening the Reporting of Observational Studies in Epidemiology checklist were used. Inverse probability of treatment weighting, univariable and multivariable logistic regression, and the Kaplan-Meier method was utilized. RESULTS: There were 203 patients with 1388 brain metastases across 11 international institutions in 4 countries with a median follow-up of 15.6 months. The rates of symptomatic RN were 9.4% and 8.2% in the concurrent and nonconcurrent groups, respectively ( P =.766). On multivariable logistic regression, V12 ≥ 10 cm 3 (odds ratio [OR]: 2.76; P =.006) and presence of BRAF mutation (OR: 2.20; P =.040) were associated with an increased risk of developing symptomatic RN; the use of concurrent over nonconcurrent therapy was not associated with an increased risk (OR: 1.06; P =.877). There were 20 grade 3 toxic events reported, and no grade 4 events reported. One patient experienced a grade 5 intracranial hemorrhage. The median overall survival was 36.1 and 19.8 months for the concurrent and nonconcurrent groups (log-rank P =.051), respectively. CONCLUSION: Concurrent administration of ICIs and SRS are not associated with an increased risk of RN. Tumors harboring BRAF mutation, or perhaps prior exposure to targeted agents, may increase this risk. Radiosurgical optimization to maintain V12 < 10 cm 3 is a potential strategy to reduce the risk of RN.
Implantable Peripheral Nerve Stimulation for Peripheral Neuropathic Pain: A Systematic Review of Prospective Studies
Char, Steven , Jin, Max Y. , Francio, Vinicius Tieppo , Hussain, Nasir , Wang, Eric J. , Morsi, Mahmoud , Orhurhu, Vwaire , Fink, Adam, D’Souza, Ryan S. , D'Souza, Ryan S , Tieppo Francio, Vinicius , Wang, Eric , Prokop, Larry J. , Fink, Adam

Mayo Clinic

Biomedicines | October 17, 2022 | Volume: 10 | Issue: 10 | Pages: 2606

10.3390/biomedicines10102606 | PMID 36289867 Get It

Peripheral nerve stimulation (PNS) has been utilized for over 50 years with accumulating evidence of efficacy in a variety of chronic pain conditions. The level and strength of evidence supporting the use of PNS for peripheral neuropathic pain remains unclear. The purpose of this review is to synthesize data from prospective studies on the efficacy of PNS for neuropathic pain as it pertains to pain intensity, neurological deficits/neuropathy (e.g., weakness, sensory deficits, gait/balance), and other secondary outcomes (quality of life, satisfaction, emotional functioning, and adverse events). In compliance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines, this review identified articles from MEDLINE(R), EMBASE, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and Scopus. Overall, per the Grading of Recommendations Assessment, Development and Evaluation (GRADE) criteria, pooled results demonstrate very low quality or low quality of evidence supporting modest to substantial improvement in pain and neurological function after PNS implantation for treatment of peripheral neuropathic pain. PNS for phantom limb pain was the only indication that had moderate level evidence. Future prospective and well-powered studies are warranted to assess the efficacy of PNS for peripheral neuropathic pain.
Analyses of plasma inflammatory proteins reveal biomarkers predictive of subsequent development of giant cell arteritis: a prospective study
Wadström, Karin , Mohammad, Aladdin J , Warrington, Kenneth J. , Matteson, Eric L. , Jakobsson, Magnus E. , Turesson, Carl , Mohammad, Aladdin J , Warrington, Kenneth J , Turesson, Carl , Jacobsson, L.

Mayo Clinic

Rheumatology | October 17, 2022 | Volume: 62 | Issue: 6 | Pages: 2304-2311

10.1093/rheumatology/keac581 | PMID 36255228 Get It

Abstract Objective To investigate the relation between biomarkers of inflammation and subsequent development of GCA. Method Participants in the population-based Malmö Diet Cancer Study (MDCS; N = 30 447), established 1991–96, who were subsequently diagnosed with GCA, were identified in a structured process. GCA-free controls, matched for sex, year of birth and year of screening were selected from the study cohort. Baseline plasma samples were analysed using the antibody-based OLINK proteomics inflammation panel (92 inflammatory proteins). Analyses were pre-designated as hypothesis-driven or hypothesis-generating. In the latter, principal component analysis was used to identify groups of proteins that explain the variance in the proteome. Within components selected based on eigenvalues, proteins with a factor loading of &gt;0.50 were investigated. Results Ninety-four cases with a confirmed incident diagnosis of GCA (median 11.9 years after inclusion) were identified. Among biomarkers with a priori hypotheses, IFN-γ was positively associated with GCA [odds ratio (OR) per s.d. 1.52; 95% CI 1.00, 2.30]. Eight biomarkers in the hypothesis-generating analyses were significantly associated with development of GCA. Among these, higher levels of IFN-γ (OR 2.37; 95% CI 1.14, 4.92) and monocyte chemotactic protein 3 (MCP3) (OR 4.27; 95% CI 1.26, 14.53) were particularly associated with increased risk of GCA in the subset sampled &lt;8.5 years before diagnosis. Several other proteins known to be important for T cell function were also associated with GCA in these analyses, e.g. CXCL9, IL-2, CD40 and CCL25. Conclusion Elevated IFN-γ levels were found years prior to diagnosis of GCA. T cell activation may precede the clinical onset of GCA.
Acute myocarditis associated with desmosomal gene variants
Raimondi, F, Olivotto, Iacopo, Peretto, G, Merlo, M, Camici, P G, Ammirati, Enrico , Piriou, Nicolas , Mohiddin, Saidi , Imazio, Massimo , Aquaro, Giovanni Donato , Olivotto, Iacopo , Heyning, Caroline M. Van De , Merlo, M, Klaassen, Sabine , Poller, Wolfgang , Adler, Eric D , Cooper, Leslie T.

Mayo Clinic

European Heart Journal | October 15, 2022 | Volume: 43 | Issue: Supplement_2 | Pages: No page available

10.1093/eurheartj/ehac544.1682 Get It

Abstract Background The risk of adverse cardiovascular events in patients with acute myocarditis (AM) and desmosomal gene variants (DGV) remains unknown. Purpose To ascertain the risk of death, ventricular arrhythmias, recurrent myocarditis, and heart failure (main endpoint) in patients with AM and pathogenic or likely pathogenetic DGV. Methods In a retrospective international study from 23 hospitals, 97 patients were included: 36 with AM and DGV (DGV(+)), 25 with AM and negative gene testing (DGV(−)), and 36 AM patients without genetics (w/o genetics). All patients had troponin elevation plus findings consistent with AM on histology or at cardiac magnetic resonance imaging (CMRI). In 86 patients CMRI changes in function and structure were re-assessed at follow-up. Results In the DGV(+) AM group (88.9% DSP variants), median age was 24 years, 91.7% presented with chest pain, and median left ventricular (LV) ejection fraction was 56% on CMRI (p=NS vs. the other 2 groups). Kaplan-Meier curves demonstrated a higher risk of the main endpoint in DGV(+) AM compared to DGV(−) and w/o genetics patients (62.3% vs. 17.5% vs. 5.3% at 5 years respectively; p&lt;0.0001), driven by myocarditis recurrence and ventricular arrhythmias (Figure 1A, B). At follow-up CMRI, a higher number of late-gadolinium enhanced segments was found in DGV(+) AM. Conclusions Patients with AM and evidence of DGV have a higher incidence of adverse cardiovascular events compared with AM patients without DGV. Further prospective studies are needed to ascertain if genetic testing might improve risk stratification of patients with AM who are considered at low risk. Funding Acknowledgement Type of funding sources: Public grant(s) – National budget only. Main funding source(s): Italian Ministry of Health
Cardiometabolic predictors of quantitative high-risk plaque features in a diverse patient population
Arce, J. , Fattouh, Michael, Skendelas, John P. , Daich, J, Zhang, L, Shaw, L J, Williamson, Eric E. , Berman, David S. , García, Mario J. , Kuno, Toshiki , Sarkar, Souvik , Daich, Jonathan , Schenone, Aldo L. , Slomka, Piotr J , Berman, D S, Dey, Damini , Slipczuk, Leandro

Mayo Clinic

European Heart Journal | October 15, 2022 | Volume: 43 | Issue: Supplement_2 | Pages: No page available

10.1093/eurheartj/ehac544.215 Get It

Abstract Background/Introduction Little is known about the prevalence of high-risk plaque features or cardiometabolic predictors in diverse patient populations with underrepresented minorities, in the setting of stable chest pain. Purpose The goals of our study are to 1) describe plaque characteristics in a diverse patient population with underrepresented minorities and 2) characterize cardiometabolic risk factors associated with high prevalence of high-risk quantitative low attenuation noncalcified plaque (LDNCP) burden. Methods Our study included patients with chest pain undergoing CCTA between June 2016 and October 2021 for stable chest pain, who had a complete cardiometabolic panel including lipoprotein(a) and lipid panel, and at least one blood pressure recording before CCTA. Patients with prior PCI or CABG where excluded. CACS was performed before CCTA as per Agatston method and quantified in Agatston Units (AU). Stenosis was graded as per SCCT guidelines by cardiologists and radiologists with level 3 cardiac CT expertise. Plaque measurements were performed using previously validated semiautomated software (AutoPlaque version 2.5) in all patients with CAD-RADS &gt;0 by expert readers blinded from patients' characteristics. Coronary atherosclerotic plaque volumes were measured. Independent predictors for plaque on CCTA among patients were examined using Wilcox multivariate logistic regression. Results A total of 227 consecutive patients were included in our study (see table; age 55.00 [47.50–62.00] years, 63% female, 16% diabetes, 44% hypertension, 40% hyperlipidemia and 32% with current or previous smoking history). Majority of patients were Hispanic (64%) and the rest were Black (27%), White (6%) and Asian (3%). Patients with LDNCP burden &gt;4% were older (60.00 [52.00–66.50] vs 53.00 [43.75–61.00]; p&lt;0.001), more likely to be diabetic (27.7 vs 11.5%; p=0.005), hypertensive (67.7 vs 33.8%; p&lt;0.001), hyperlipidemic (64.6 vs 29.9%; p&lt;0.001) and present smokers (31.3 vs 13.9%; p=0.003). Almost all patients (63/67) with LDNCP burden &gt;4% had non-obstructive disease (CAD-RADS&lt;4). Patient with LDNCP burden &gt;4% were more likely to be on statin therapy (46.0 vs 30.4%; p=0.041). There was no differences in ethnicity, hemoglobin A1C, TC, LDL-C, HLD-C, TGs, lipoprotein(a), SBP or DBP. By logistic regression analysis, age (OR [CI]: 1.06 [1.01–1.08]), hypertension (2.20, [1.06–4.63]) and hyperlipidemia (2.73 [1.37–5.47]) increased the likelihood of LDNCP burden &gt;4%, but not Lipoprotein (a)&gt;175 nmol/L (OR [CI]: 1.07 [0.48–2.31]. Conclusions In our cohort of patients with high number of unrepresented minorities presenting with stable chest pain, almost all patients (94%) with LDNCP burden &gt;4% had non-obstructive CAD (CAD-RADS&lt;4). There were no differences in prevalence of LDNCP or CAD-RADS among different ethnic groups. Age, hypertension and hyperlipidemia, were the cardiometabolic factors related to LDNCP burden &gt;4%. Funding Acknowledgement Type of funding sources: None.
NCCN Guidelines® Insights: Survivorship, Version 1.2022
Sanft, Tara , Peterson, Lindsay L. , Rodriguez, Maria Alma , Ansbaugh, Shannon, Demark‐Wahnefried, Wendy , Dickinson, Kristin , Fairman, Nathan, Goldman, Mindy, Henry, N. Lynn , Hill‐Kayser, Christine E. , Khakpour, Nazanin , Koura, Divya, McDonough, Allison L. , Melisko, Michelle , Mooney, Kathi , Moryl, Natalie , Neuman, Heather B. , Patel, Chirayu G. , Porpiglia, Andrea S., Ruddy, Kathryn J. , Schapira, Lidia , Shockney, Lillie D. , Syrjala, Karen L. , Yang, Eric H. , Zee, Phyllis C. , McMillian, Nicole R., Freedman-Cass, Deborah A., Broderick, Gregory, Henry, N Lynn , Yang, Eric , Demark-Wahnefried, Wendy , Day, Andrew T. , Armenian, Saro H. , Baker, Kevin Scott , Ballinger, Tarah Jean , Broderick, Gregory A. , Friedman, Debra L. , Hudson, Melissa M. , Moore, Halle C. F. , O’Connor, Tracey L. , Overholser, Linda , Paskett, Electra D. , Pirl, William F. , Smith, Sophia K. , Tevaarwerk, Amyé

Mayo Clinic

Journal of the National Comprehensive Cancer Network | October 14, 2022 | Volume: 20 | Issue: 10 | Pages: 1080-1090

10.6004/jnccn.2022.0052 | PMID 36240847 Get It

The NCCN Guidelines for Survivorship are intended to help healthcare professionals who work with survivors to ensure that the survivors’ complex and varied needs are addressed. The NCCN Guidelines provide screening, evaluation, and treatment recommendations for the consequences of adult-onset cancer and its treatment; recommendations to help promote physical activity, weight management, and immunizations in survivors; and a framework for care coordination. This article summarizes updates to the NCCN Guidelines pertaining to preventive health for cancer survivors, including recommendations about alcohol consumption and vaccinations.
Genomic Microsatellite Signatures Identify Germline Mismatch Repair Deficiency and Risk of Cancer Onset
Chung, Jiil , Negm, Logine , Bianchi, Vanessa , Das, Anirban , Liu, Zhihui Amy , Sudhaman, Sumedha, Aronson, Melyssa , Brunga, Ledia , Forster, Victoria J. , Komosa, Martin, Davidson, Scott , Lees, Jodi, Tomboc, Patrick , Samuel, David , Bendel, Anne , Knipstein, Jeffrey , Schneider, Kami Wolfe , Reschke, Agnes , Zelcer, Shayna , Zorzi, Alexandra P., Bedgood, Raymond , Peterson, Lindsay L. , Rhode, Sara , Damme, An Van , Scheers, Isabelle , Robbins, Gabriel , Vanan, Magimairajan , Burke, Carol A. , Villani, Anita , Malkin, David , Durno, Carol , Hawkins, Cynthia , Maruvka, Yosef E. , Tabori, Uri , Das, Anirban , Aronson, Melyssa , Forster, Victoria , Davidson, Scott , Tomboc, Patrick , Knipstein, Jeffrey , Schneider, Kami Wolfe , Reschke, Agnes , McWilliams, Robert R , Foulkes, William D , Bedgood, Raymond , Peterson, Lindsay , Van Damme, An , Robbins, Gabriel , Vanan, Magimairajan Issai , Meyn, M Stephen , Auer, Rebecca , Leach, Brandie , Villani, Anita , Malkin, David , Bouffet, Eric , Hawkins, Cynthia , Maruvka, Yosef E , Tabori, Uri , Burke, Carol A , Stengs, Lucie K. , Sudhaman, Sumedha , Edwards, Melissa , Farah, Roula Antoine , McWilliams, Robert R. , Foulkes, William D. , Gardner, Sharon L , Bouffet, Éric , Huang, Annie , Taylor, Michael D. , Shlien, Adam , Getz, Gad

Mayo Clinic

Journal of Clinical Oncology | October 14, 2022 | Volume: 41 | Issue: 4 | Pages: 766-777

10.1200/jco.21.02873 | PMID 36240479 Get It

PURPOSE Diagnosis of Mismatch Repair Deficiency (MMRD) is crucial for tumor management and early detection in patients with the cancer predisposition syndrome constitutional mismatch repair deficiency (CMMRD). Current diagnostic tools are cumbersome and inconsistent both in childhood cancers and in determining germline MMRD. PATIENTS AND METHODS We developed and analyzed a functional Low-pass Genomic Instability Characterization (LOGIC) assay to detect MMRD. The diagnostic performance of LOGIC was compared with that of current established assays including tumor mutational burden, immunohistochemistry, and the microsatellite instability panel. LOGIC was then applied to various normal tissues of patients with CMMRD with comprehensive clinical data including age of cancer presentation. RESULTS Overall, LOGIC was 100% sensitive and specific in detecting MMRD in childhood cancers (N = 376). It was more sensitive than the microsatellite instability panel (14%, P = 4.3 × 10 −12 ), immunohistochemistry (86%, P = 4.6 × 10 −3 ), or tumor mutational burden (80%, P = 9.1 × 10 −4 ). LOGIC was able to distinguish CMMRD from other cancer predisposition syndromes using blood and saliva DNA ( P < .0001, n = 277). In normal cells, MMRDness scores differed between tissues (GI > blood > brain), increased over time in the same individual, and revealed genotype-phenotype associations within the mismatch repair genes. Importantly, increased MMRDness score was associated with younger age of first cancer presentation in individuals with CMMRD ( P = 2.2 × 10 −5 ). CONCLUSION LOGIC was a robust tool for the diagnosis of MMRD in multiple cancer types and in normal tissues. LOGIC may inform therapeutic cancer decisions, provide rapid diagnosis of germline MMRD, and support tailored surveillance for individuals with CMMRD.